The breadth of protection mediated by anti-N2 neuraminidase antibody responses relies on cross-reactive and not cross-inhibiting antibodies
Amelinck, L.; Smet, A.; Ysenbaert, T.; Sedeyn, K.; Gomila, R.; Warren, W.; Vogel, T. U.; Saelens, X.; Catani, J. P. P.
Show abstract
Neuraminidase (NA) inhibition (NAI) titers have been identified as an independent correlation of protection against influenza. Few studies, however, have investigated the breadth of NA-based immune protection. Previously, we have reported that N2 NAs derived from human H3N2 viruses that circulated between 2009 and 2017 can be subdivided into four antigenic groups. Here, we immunized mice with recombinant soluble tetrameric NA from H3N2 strains representing those four antigenic groups or passively transferred N2 NA immune serum into naive mice to evaluate the breadth of protection against a heterologous HxN2 influenza virus challenge. We show that the breadth of protection goes beyond the breadth of NAI but still requires the presence of cross-reactive antibodies. Interestingly, in the absence of cross-reactive antibodies, the immunization of DBA/2J mice with heterologous NA was associated with an early onset of disease upon challenge with the reassortant HxNind11 or H2N2 A/Singapore/1/1957.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters 97%
- Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Proteinco-immunization in rhesus macaques 96%
- Alpha-defensin binding expands human adenovirus tropism 96%
Similar papers in this journal
Similar papers in this journal
- Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model 97%
- Nucleoside-modified mRNA-based influenza vaccines circumvent problems associated with H3N2 vaccine strain egg-adaptation 96%
- Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2 96%
Similar papers in this journal
- Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus 96%
- Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion 96%
- Greater breadth of vaccine-induced immunity in females than males is mediated by increased antibody diversity in germinal center B cells 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.